<DOC>
	<DOC>NCT01860794</DOC>
	<brief_summary>The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease.</brief_summary>
	<brief_title>Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease</brief_title>
	<detailed_description>This study is phase I/II clinical trials which is accessible to those involved in the study and conducted by only Bundang CHA hospital. The progress of the clinical trails is reported to and evaluated by Data monitoring committee before the enrolment of next human subject.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>1. Female patients with idiopathic or primary Parkinson's disease 2. Hoehn and Yare (HY) stage III or IV 3. more than 33% improvement Part III UPDRS score after one injection of levodopa in the morning 4. Patients aged less than 70 5. Great decrease of dopamine uptake in putamen, particularly posterior part, in Positron emission tomograph(PET) before surgery 1. Atypical or secondary parkinsonism 2. Medical history of severe depression with Beck Depression Inventory(BDI) scores greater than 30 3. Psychological disorders (illusion, delusion, schizophrenia) 4. Dementia with KMMSE(Korean minimental state examination) scores less than 24 5. Epilepsy 6. Medial history of brain surgery 7. Medical history of other brain diseases 8. Hemorrhagic tendency 9. Severe internal diseases such as poor general condition, hypertension, chronic respiratory disease, ischemic heart disease, cancer 10. Experience of participating in clinical trial within 30 days 11. Female patients who have the chances of getting pregnant during clinical trial and do not use the approved birth controls 12. Pregnant or lactating women 13. Patients who are not considered to be eligible to participate in clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>